Loading chat...
ND SCR4016
Concurrent Resolution
Status
Passed
4/7/2015
Primary Sponsor
Joan Heckaman
Click for details
AI Summary
- Urges Congress and the President to direct the FDA to allow use of experimental medications to treat PKAN for three children of the Kulsrud family in Grace City, North Dakota
- Notes the three children have been diagnosed with PKAN, with the oldest having reached average life expectancy and the other two rapidly progressing into later disease stages
- States experimental treatments are available that could prolong the children's lives and improve their overall quality of life
- Requires the Secretary of State to forward copies of the resolution via certified mail to the U.S. Surgeon General, FDA Commissioner, and each member of the North Dakota Congressional Delegation
- Urges Congress and the President to direct the FDA to review and update the Compassionate Care application process to benefit a greater number of terminally ill patients
Legislative Description
A concurrent resolution urging Congress and the President of the United States to direct the federal Food and Drug Administration to allow the use of experimental medications to treat Pantothenate kinase-associated neurodegeneration (PKAN) for the benefit of the three children of the Kulsrud family living in Grace City, North Dakota.
Last Action
Filed with Secretary Of State 04/07
4/7/2015
Committee Referrals
Health and Human Services1/26/2015
Full Bill Text
No bill text available